A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

Who Took Part

According to the abstract, 1, subjects were involved.

In cohort 1, subjects (N = 36) were exposed once each to SARAsp -Mix, NN-Mix-US and NN-Mix-EU.

In cohort 2, subjects (N = 16) were exposed once each to SARAsp -Mix and SAR-Asp.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the subjects took both Insulin Aspart and the comparison in turn, acting as their own control.

This was a randomized, double-blind, crossover trial in two cohorts.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Glucose Clamp Technique, Hypoglycemic Agents and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 1, subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page.